Accuitis

Executive Summary

Accuitis is a preclinical-stage biotechnology company based in San Diego, focused on developing small molecule therapies that restore mitochondrial sirtuin 3 (SIRT3) expression to combat neurodegenerative diseases. Their lead compound has shown promise in extensive preclinical research for indications including Alzheimer's disease, Parkinson's disease, and methamphetamine addiction. By targeting mitochondrial dysfunction, Accuitis aims to restore healthy cellular function in these debilitating conditions. As a private company founded in 2015, Accuitis has not yet disclosed total funding or valuation, indicating it is likely in early development stages. With no current pipelines or regulatory milestones, the company's progress hinges on advancing its lead candidate toward clinical trials.

Upcoming Catalysts (preview)

• Q3 2026IND Filing for Lead Compound30% success
• Q3 2026Series A Funding Round50% success
• TBDPreclinical Data Publication in Peer-Reviewed Journal60% success